

1-921 U.S. PTO  
01/04/02

Please type a plus sign (+) inside this



1-7-02

PTO/SB/05 (11-00)

Approved for use through 10/31/2002. OMB 0651-0032  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 C.F.R. § 1.53(b))

Attorney Docket No. 14538A-005111US

First Inventor Koff, Andrew

Title METHODS FOR ENHANCING ANIMAL GROWTH AND CELL  
PROLIFERATION BY ELIMINATION OF THE CYCLIN-DEPENDENT  
KINASE INHIBITOR FUNCTION OF P27KIP1

Express Mail Label No. ET949700515US

## APPLICATION ELEMENTS

See MPEP chapter 600 concerning design patent application contents.

1. ☐ Fee Transmittal Form (e.g., PTO/SB/17)  
(Submit an original and a duplicate for fee processing)
2. ☒ Applicant claims small entity status.  
See 37 CFR 1.27.
3. ☒ Specification [Total Pages 56]  
(preferred arrangement set forth below)
  - Descriptive title of the Invention
  - Cross References to Related Applications
  - Statement Regarding Fed sponsored R & D
  - Reference to sequence listing, a table, or a computer program listing appendix
  - Background of the Invention
  - Brief Summary of the Invention
  - Brief Description of the Drawings (if filed)
  - Detailed Description
  - Claim(s)
  - Abstract of the Disclosure
4. ☒ Drawing(s) (35 U.S.C.113) [Total Sheets 15]
5. Oath or Declaration [Total Pages]
  - a. ☐ Newly executed (original or copy)
  - b. ☐ Copy from a prior application (37 CFR 1.63 (d))  
(for a continuation/divisional with Box 18 completed)
  - i. ☐ DELETION OF INVENTOR(S)  
Signed statement attached deleting inventor(s)  
named in the prior application, see 37 CFR  
1.63(d)(2) and 1.33(b).
6. ☐ Application Data Sheet. See 37 CFR 1.76

## ADDRESS TO

Assistant Commissioner for Patents  
Box Patent Application  
Washington, DC 20231

7. ☐ CD-ROM or CD-R in duplicate, large table or  
Computer Program (Appendix)
8. Nucleotide and/or Amino Acid Sequence Submission  
(if applicable, all necessary)
  - a. ☐ Computer Readable Form (CRF)
  - b. Specification Sequence Listing on:
    - i. ☐ CD-ROM or CD-R (2 copies); or
    - ii. ☐ paper number of pages
  - c. ☐ Statements verifying identity of above copies

## ACCOMPANYING APPLICATIONS PARTS

9. ☐ Assignment Papers (cover sheet & document(s))
10. ☐ 37 C.F.R. § 3.73(b) Statement ☐ Power of  
(when there is an assignee) Attorney
11. ☐ English Translation Document (if applicable)
12. ☐ Information Disclosure ☐ Copies of IDS  
Statement (IDS)/PTO-1449 Citations
13. ☐ Preliminary Amendment
14. ☒ Return Receipt Postcard (MPEP 503)  
(Should be specifically itemized)
15. ☐ Certified Copy of Priority Document(s)  
(if foreign priority is claimed)
16. ☐ Nonpublication Request under 35 U.S.C.  
122(b)(2)(B)(i). Applicant must attach form PTO/SB/35  
or its equivalent
17. ☒ Other: Application cover page; Cert. of Mailing

18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:

☒ Continuation ☐ Divisional ☐ Continuation-in-part (CIP)

of prior application No: 08/ 973,823

Prior application information: Examiner R. Shukla

Group Art Unit: 1632

For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

## 19. CORRESPONDENCE ADDRESS

☒ Customer Number or Bar Code Label

20350

(Insert Customer No. or Attach bar code label here)

or ☐ Correspondence address below

Name

Address

City

State

Zip Code

Country

Telephone

Fax

Name (Print/Type)

Mark G. Sandbaken, Ph.D.

Registration No. (Attorney/Agent)

39,354

Signature

Date

01-04-02

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231. SE 5011378 v1

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

INVENTOR: Andrew Koff  
Hiroaki Kiyokawa

ASSIGNEE: Sloan-Kettering Institute for Cancer Research

APPLICATION NO.: n/a GAU: n/a

FILING DATE: January 4, 2002

TITLE: METHODS FOR ENHANCING ANIMAL  
GROWTH AND CELL PROLIFERATION BY  
ELIMINATION OF THE CYCLIN-  
DEPENDENT KINASE INHIBITOR  
FUNCTION OF P27<sup>Kip1</sup>

ATTORNEY DOCKET: 14538A-005111US

Assistant Commissioner for Patents  
Box PATENT APPLICATION  
Washington, D.C. 20231

**CERTIFICATE OF MAILING  
(Express Mail)**

Honorable Assistant Commissioner:

I hereby certify that the attached correspondence [U.S. PATENT APPLICATION] is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee," Express Mail Label No. ET949700515US (according to C.F.R. §1.10) on this 4<sup>th</sup> day of January, 2002 with sufficient postage and in an envelope addressed to the Assistant Commissioner for Patents, Box PATENT APPLICATION, Washington, D.C. 20231.

Susan M. Foley  
Signature of registered practitioner or other  
person actually making the deposit pursuant  
to 37 C.F.R. §1.10(b).

Susan Foley  
Name of person signing above